AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:05 2025-07-14 EDT			5-day change	1st Jan Change
10,662.00 ^GBX	+2.03%		+4.35%	+1.85%

07-14	European Equities Close Mixed in Monday Trading; EU Signals Readiness to Retaliate Against US Tariffs	MT
07-14	UK Shares Start Week in Green on Government Stimuli; AstraZeneca Adds 2%	MT

AstraZeneca signs AI research deal with China's CSPC for chronic diseases

Published on 2025-06-13 at 05:17, updated on 2025-06-13 at 06:49

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about AstraZeneca PLC

European Equities Close Mixed in Monday Trading; EU Signals Readiness to Retaliate Against US Tariffs	07-14	MT
UK Shares Start Week in Green on Government Stimuli; AstraZeneca Adds 2%	07-14	MT
ASTRAZENECA : UBS remains its Buy rating	07-14	ZD
FTSE 100 hits fresh record high on rate cut optimism	07-14	RE
FTSE 100 hits fresh record high on rate cut optimism	07-14	RE
European shares end lower as Trump's tariff threats keep markets on edge	07-14	RE
European shares end lower as Trump's tariff threats keep markets on edge	07-14	RE
FTSE 100 thrives but tariff threat hurts Europe	07-14	AN
AstraZeneca plc Announces Baxdrostat Met the Primary and All Secondary Endpoints in BaxHTN Phase III Trial in Patients with Undunded or Treatment Resistant Hypertension	07-14	CI
Astrazeneca's Phase 3 Trial of Baxdrostat in Hypertension Meets Primary, Secondary Endpoints	07-14	MT
AstraZeneca drug lowers high blood pressure in late-stage study; shares rise	07-14	RE
ASTRAZENECA : JP Morgan keeps its Buy rating	07-14	ZD
AstraZeneca: conclusive results against hypertension	07-14	CF
Stockholm Bullets: Lifco Plummets After Missing Expectations	07-14	FW
AstraZeneca drug may lead to lower blood pressure, trial suggests	07-14	AN
FTSE 100 up but tariff woe hits European peers	07-14	AN
AstraZeneca drug meets all goals in high blood pressure study	07-14	RE
AstraZeneca says baxdrostat met primary and secondary endpoints in Phase III trial	07-14	RE
AstraZeneca's Hypertension Drug Meets Primary Endpoints in Phase 3 Trial	07-14	MT
FDA May Fast Track Drug Reviews for Lower US Prices	07-11	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	07-11	MT
Britain's FTSE 100 notches record close, buoyed by miners	07-10	RE
Britain's FTSE 100 notches record close, buoyed by miners	07-10	RE
Eolas Therapeutics entered new agreement with AstraZeneca	07-10	RE
Record-setting FTSE 100 shines on tariff hope	07-10	AN

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

07-29 - Q2 2025 Earnings Release

More about the company